Find Sotorasib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Amg-510, Amg510, 2296729-00-3, Lumakras, Amg-510 racemate, Amg 510
Molecular Formula
C30H30F2N6O3
Molecular Weight
560.6  g/mol
InChI Key
NXQKSXLFSAEQCZ-SFHVURJKSA-N
FDA UNII
2B2VM6UC8G

Sotorasib
Sotorasib is an orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.
1 2D Structure

Sotorasib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
2.1.2 InChI
InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1
2.1.3 InChI Key
NXQKSXLFSAEQCZ-SFHVURJKSA-N
2.1.4 Canonical SMILES
CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C
2.1.5 Isomeric SMILES
C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C
2.2 Other Identifiers
2.2.1 UNII
2B2VM6UC8G
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2s)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one

2. Amg 510

3. Amg-510

4. Amg510

5. Lumakras

2.3.2 Depositor-Supplied Synonyms

1. Amg-510

2. Amg510

3. 2296729-00-3

4. Lumakras

5. Amg-510 Racemate

6. Amg 510

7. 2252403-56-6

8. Kras G12c Inhibitor 9

9. Sotorasib [inn]

10. Sotorasib [usan]

11. Kras Mutant-targeting Amg 510

12. 4-((s)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1h)-one

13. 2b2vm6uc8g

14. Chembl4535757

15. 2296729-00-3 (racemate)

16. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2s)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one

17. (1m)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2s)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1h)-one

18. (1s)-4-((s)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1h)-one

19. 2296729-66-1

20. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2s)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one

21. Pyrido(2,3-d)pyrimidin-2(1h)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2s)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-

22. Sotorasibum

23. Lumykras

24. Pyrido(2,3-d)pyrimidin-2(1h)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2s)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-, (1r)-

25. Pyrido[2,3-d]pyrimidin-2(1h)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2s)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-, (1r)-

26. Amg510 Racemate

27. Amg 510 Racemate

28. Amg-510(racemate)

29. Sotorasib [jan]

30. Sotorasib Racemate

31. Unii-2b2vm6uc8g

32. Sotorasib [who-dd]

33. Sotorasib [orange Book]

34. Schembl20560375

35. Gtpl10678

36. Chebi:178199

37. Amg 510 Pound>>amg-510

38. Dtxsid001099260

39. Glxc-25372

40. Amy16918

41. Bcp30452

42. Bcp33368

43. Ex-a3538

44. Bdbm50514402

45. Nsc818433

46. S8830

47. Who 11370

48. Akos037649138

49. Db15569

50. Nsc-818433

51. Ac-35168

52. Ba172505

53. Ba172506

54. Bs-16684

55. Hy-114277

56. Cs-0081316

57. Compound (r)-38 [pmid: 31820981]

58. D70074

59. D77975

60. A930071

61. A934531

62. Amg510 ; Amg 510; Amg-510; Amg510

63. (1r)-4-((s)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1h)-one

64. (1ra)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-((2s)-2-methyl-4-(1-oxoprop-2-en-1-yl)piperazin-1-yl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)pyrido(2,3-d)pyrimidin-2(1h)-one

65. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1m)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2s)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1h)-one

66. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(2-propanyl)-3-pyridinyl]-4-[(2s)-2-methyl-4-(2-propenoyl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1h)-one

67. 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2s)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1h)-one

2.4 Create Date
2019-01-26
3 Chemical and Physical Properties
Molecular Weight 560.6 g/mol
Molecular Formula C30H30F2N6O3
XLogP34
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass560.23474516 g/mol
Monoisotopic Mass560.23474516 g/mol
Topological Polar Surface Area102 Ų
Heavy Atom Count41
Formal Charge0
Complexity1030
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Sotorasib is indicated in the treatment of adults with KRAS G12C mutant non small cell lung cancer.


Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Sotorasib is indicated in the treatment of adults with KRAS G12C mutant non small cell lung cancer. It has a moderate duration of action as it is given daily. Patients should be counselled regarding the risks of hepatotoxicity, interstitial lung disease and pneumonitis; and to avoid breastfeeding during treatment and up to 1 week after the last dose.


5.2 MeSH Pharmacological Classification

Immune Checkpoint Inhibitors

Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. (See all compounds classified as Immune Checkpoint Inhibitors.)


5.3 ATC Code

L01XX73


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01X - Other antineoplastic agents

L01XX - Other antineoplastic agents

L01XX73 - Sotorasib


5.4 Absorption, Distribution and Excretion

Absorption

A 960 mg once daily dose of sotorasib reaches a Cmax of 7.50 g/mL, with a median Tmax of 2.0 hours, and an AUC0-24h of 65.3 h\*g/mL.


Route of Elimination

Sotorasib is 74% eliminated in the feces and 6% eliminated in the urine. 53% of the dose recovered in the feces and 1% of the dose recovered in the urine is in the form of the unchanged parent compound.


Volume of Distribution

The volume of distribution of sotorasib is 211 L.


Clearance

Sotorasib has an apparent clearance at steady state of 26.2 L/h.


5.5 Metabolism/Metabolites

Sotorasib is predominantly metabolized through conjugation or by CYP3As.


5.6 Biological Half-Life

Sotorasib has a terminal elimination half life of 5.5 1.8 hours.


5.7 Mechanism of Action

Normally GTP binds to KRAS, activating the protein and promoting effectors to the MAP kinase pathway. GTP is hydrolyzed to GDP, and KRAS is inactivated. KRAS G12C mutations impair hydrolysis of GTP, leaving it in the active form. Sotorasib binds to the cysteine residue in KRAS G12C mutations, holding the protein in its inactive form. The cysteine residue that sotorasib targets is not present in the wild type KRAS, which prevents off-target effects. This mutation is present in 13% of non small cell lung cancer, 3% of colorectal and appendix cancer, and 1-3% of solid tumors.


API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712514600,"product":"LUT-81 ACTIVE PHARMACEUTICALS INGREDIETNS (API) (SOTORASIB)","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"TEVA API","supplierCountry":"CROATIA","foreign_port":"ZAGREB","customer":"SANDOZ B2B","customerCountry":"INDIA","quantity":"18.00","actualQuantity":"18","unit":"KGS","unitRateFc":"45750","totalValueFC":"831810.1","currency":"USD","unitRateINR":"3859012.5","date":"08-Apr-2024","totalValueINR":"69462225","totalValueInUsd":"831810.1","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"2934462","productDescription":"API","marketType":"REGULATED MARKET","country":"CROATIA","selfForZScoreResived":"Pharma Grade","supplierPort":"ZAGREB","supplierAddress":"PIET HEIN BUILDING PIET HEINKADE107 1019 GM AMSTERDAMTHE NETHERLANDS ANTILLES","customerAddress":"SANDOZ HOUSE"}]
08-Apr-2024
08-Apr-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty